About: ESMO Management and treatment adapted recommendations in the COVID-19 era: Breast Cancer

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: ESMO Management and treatment adapted recommendations in the COVID-19 era: Breast Cancer Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	ESMO Management and treatment adapted recommendations in the COVID-19 era: Breast Cancer
Creator	Curigliano, Giuseppe Trapani, Dario Cardoso, Fatima Cortes, Javier Cosimo, Serena Criscitiello, Carmen De Azambuja, Evandro Delaloge, Suzette Gnant, Michael Loibl, Sibylle Paluch-Shimon, Shani Poortman, Philip Senkus, Elzbieta
source	Medline; PMC
abstract	The global preparedness and response to the rapid escalation to severe acute respiratory syndrome coronavirus (SARS-CoV)-2-related disease (COVID-19) to a pandemic proportion has demanded the formulation of a reliable, useful and evidence-based mechanism for health services prioritisation, to achieve the highest quality standards of care to all patients. The prioritisation of high value cancer interventions must be embedded in the agenda for the pandemic response, ensuring that no inconsistency or discrepancy emerge in the health planning processes. The aim of this work is to organise health interventions for breast cancer management and research in a tiered framework (high, medium, low value), formulating a scheme of prioritisation per clinical cogency and intrinsic value or magnitude of benefit. The public health tools and schemes for priority setting in oncology have been used as models, aspiring to capture clinical urgency, value in healthcare, community goals and fairness, while respecting the principles of benevolence, non-maleficence, autonomy and justice. We discuss the priority health interventions across the cancer continuum, giving a perspective on the role and meaning to maintain some services (undeferrable) while temporarily abrogate some others (deferrable). Considerations for implementation and the essential link to pre-existing health services, especially primary healthcare, are addressed, outlining a framework for the development of effective and functional services, such as telemedicine. The discussion covers the theme of health systems strategising, and why oncology care, in particular breast cancer care, should be maintained in parallel to pandemic control measures, providing a pragmatic clinical model within the broader context of public healthcare schemes.
has issue date	2020-05-20(xsd:dateTime)
bibo:doi	10.1136/esmoopen-2020-000793
bibo:pmid	32439716
has license	cc-by-nc
sha1sum (hex)	5f138b67151030fc296b2154aacad6b9b91014f1
schema:url	https://doi.org/10.1136/esmoopen-2020-000793
resource representing a document's title	ESMO Management and treatment adapted recommendations in the COVID-19 era: Breast Cancer
has PubMed Central identifier	PMC7295852
has PubMed identifier	32439716
schema:publication	ESMO Open
resource representing a document's body	covid:5f138b67151030fc296b2154aacad6b9b91014f1#body_text
is schema:about of	named entity 'prognosis' named entity 'primary healthcare' named entity 'physical distancing' named entity 'breast cancer' named entity 'radiation therapy' named entity 'mTOR inhibitors' named entity 'oncology' named entity 'decision making' named entity 'asymptomatic' named entity 'Triaging' named entity 'immune-modulating' named entity 'drug holiday' named entity 'oncology' named entity 'public health interventions' named entity 'health services' named entity 'COVID-19' named entity 'endocrine' named entity 'oncology' named entity 'thromboembolic' named entity 'mTOR' named entity 'healthcare professionals' named entity 'COVID-19' named entity 'breast cancer' named entity 'breast CanCer' named entity 'radiation therapy' named entity 'imaging techniques' named entity 'contingency plan' named entity 'clinical decision making' named entity 'HER2' named entity 'health workforce' named entity 'ECGs' named entity 'chronic disease' named entity 'health services' named entity 'evidence-based' named entity 'breast CanCer' named entity 'not-for-profit' named entity 'multidisciplinary team' named entity 'COVID-19' named entity 'diagnostic imaging' named entity 'metastatic breast cancer' named entity 'older patients' named entity 'breast cancer' named entity 'health systems' named entity 'bisphosphonates' named entity 'mammography' named entity 'oncology' named entity 'breast cancer care' named entity 'trastuzumab' named entity 'intravenous' named entity 'health sector' named entity 'Ontario' named entity 'neoadjuvant' named entity 'premedication' named entity 'clinical trials' named entity 'preclinical' named entity 'clinical trial' named entity 'oncology' named entity 'mammography' named entity 'anthracycline' named entity 'MCBS' named entity 'follow-up' named entity 'COVID-19 pandemic' named entity 'risk-benefit ratio' named entity '12 weeks' named entity 'postmenopausal' named entity 'mammograms' named entity 'COVID-19' named entity 'antineoplastic' named entity 'MCBS'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software